• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Eton Pharmaceuticals Inc. (Amendment)

    4/30/24 7:00:15 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETON alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Eton Pharmaceuticals, Inc.
    (Name of Issuer)

     

    Common Stock, $0.001 par value
    (Title of Class of Securities)

     

    29772L 108
    (CUSIP Number)

     

    Harrow, Inc.

    102 Woodmont Blvd., Suite 610

    Nashville, Tennessee 37215

    Attention: Andrew R. Boll

    (615) 733-4731

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    April 26, 2024
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13D/A

     

    CUSIP No. 29772L 108

     

    1 NAMES OF REPORTING PERSONS
    Harrow, Inc.
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
     
    4 SOURCE OF FUNDS (See Instructions)
    N/A
    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
    ☐
    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    0
    8 SHARED VOTING POWER
    0
    9 SOLE DISPOSITIVE POWER
    0
    10 SHARED DISPOSITIVE POWER
    0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    0.0%
    14 TYPE OF REPORTING PERSON (See Instructions)
    CO

     

     

     

     

    This amendment (“Final Amendment”) amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission on November 23, 2018, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on January 28, 2022 (the “Amended Schedule 13D”). Capitalized terms used but not defined in this Final Amendment shall have the meanings set forth in the Amended Schedule 13D. Except as specifically amended by this Final Amendment, the Amended Schedule 13D is unchanged.

     

    Item 2. Identity and Background.

     

    Item 2(a) of the Amended Schedule 13D is hereby amended and restated to read as follows:

     

    (a) This Schedule 13D is being filed by Harrow, Inc. (formerly known as Harrow Health, Inc. and Imprimis Pharmaceuticals, Inc.) (the “Reporting Person”).

     

    Item 4. Purpose of the Transaction.

     

    Item 4 of the Amended Schedule 13D is amended by adding the following:

     

    On April 26, 2024, the Reporting Person sold all 1,982,000 shares of Common Stock of the Issuer previously owned by the Reporting Person in a block trade at a gross price of $3.00 per share.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of the Amended Schedule 13D is amended and restated to read as follows:

     

    (a) – (b) As of the date hereof, the Reporting Person does not beneficially own any shares of Common Stock, nor does the Reporting Person have or share the power to vote or to direct the vote, or the power to dispose or direct the disposition of, any shares of Common Stock.

     

    (c) Except as described in Item 4, the Reporting Person has not effected any transactions in Common Stock of the Registrant during the past 60 days.

     

    (d) The Reporting Person has the right to receive and the power to direct the proceeds from the sale of the Common Stock covered by this Statement on Schedule 13D.

     

    (e) On April 26, 2024, following the transaction reported herein, the Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    April 30, 2024 Harrow, Inc.
         
      By: /s/ Andrew R. Boll
        Andrew R. Boll
        Chief Financial Officer

     

     

     

    Get the next $ETON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ETON

    DatePrice TargetRatingAnalyst
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    1/10/2025$21.00Buy
    B. Riley Securities
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    9/4/2024$9.00Buy
    H.C. Wainwright
    5/6/2024$8.00Buy
    Craig Hallum
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $ETON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/12/25 4:32:51 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      10/25/24 4:05:24 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      10/8/24 6:34:32 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Krempa David sold $504,318 worth of shares (34,000 units at $14.83), decreasing direct ownership by 5% to 612,646 units (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/16/25 4:56:08 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/12/25 4:32:51 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Brynjelsen Sean sold $3,592,611 worth of shares (210,000 units at $17.11), decreasing direct ownership by 7% to 2,873,513 units (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/5/25 5:15:00 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care